Organoruthenium Complexes with CN Ligands are Highly Potent Cytotoxic Agents that Act by a New Mechanism of Action
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68081707%3A_____%2F17%3A00486061" target="_blank" >RIV/68081707:_____/17:00486061 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/61989592:15310/17:73583775
Výsledek na webu
<a href="http://dx.doi.org/10.1002/chem.201703581" target="_blank" >http://dx.doi.org/10.1002/chem.201703581</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/chem.201703581" target="_blank" >10.1002/chem.201703581</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Organoruthenium Complexes with CN Ligands are Highly Potent Cytotoxic Agents that Act by a New Mechanism of Action
Popis výsledku v původním jazyce
Our study demonstrates that four novel kinetically inert C,N-cyclometalated Ru-II complexes of the type [Ru(C<^>N)(N<^>N)(2)][PF6] containing a handle for functionalization on the C<^>N ligand are very potent cytotoxic agents against several different human cancer cell lines and are up to 400-fold more potent than clinically used cisplatin. In addition, the investigated ruthenium complexes are less cytotoxic in noncancerous cells, and exhibit higher selectivity for cancer cells than conventional platinum anticancer drugs. The high potency of the investigated ruthenium compounds can be attributed to several factors, including enhanced internalization and their capability to change mitochondrial transmembrane potential in cells. The new ruthenium complexes also interfere with protein synthesis with a markedly higher potency than conventional inhibitors of DNA translation. Notably, the latter mechanism has not been hitherto described for other cytotoxic Ru compounds and cisplatin.
Název v anglickém jazyce
Organoruthenium Complexes with CN Ligands are Highly Potent Cytotoxic Agents that Act by a New Mechanism of Action
Popis výsledku anglicky
Our study demonstrates that four novel kinetically inert C,N-cyclometalated Ru-II complexes of the type [Ru(C<^>N)(N<^>N)(2)][PF6] containing a handle for functionalization on the C<^>N ligand are very potent cytotoxic agents against several different human cancer cell lines and are up to 400-fold more potent than clinically used cisplatin. In addition, the investigated ruthenium complexes are less cytotoxic in noncancerous cells, and exhibit higher selectivity for cancer cells than conventional platinum anticancer drugs. The high potency of the investigated ruthenium compounds can be attributed to several factors, including enhanced internalization and their capability to change mitochondrial transmembrane potential in cells. The new ruthenium complexes also interfere with protein synthesis with a markedly higher potency than conventional inhibitors of DNA translation. Notably, the latter mechanism has not been hitherto described for other cytotoxic Ru compounds and cisplatin.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
10608 - Biochemistry and molecular biology
Návaznosti výsledku
Projekt
<a href="/cs/project/GA17-05302S" target="_blank" >GA17-05302S: Protinádorově účinná metalofarmaka cílená na rakovinné kmenové buňky. Studie mechanismu působení</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2017
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Chemistry - A European Journal
ISSN
0947-6539
e-ISSN
—
Svazek periodika
23
Číslo periodika v rámci svazku
61
Stát vydavatele periodika
DE - Spolková republika Německo
Počet stran výsledku
5
Strana od-do
15294-15299
Kód UT WoS článku
000414351400006
EID výsledku v databázi Scopus
—